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Abstract
Background: Novel biological and precision therapies and their associated predictive biomarker tests offer
opportunities for increased tumor response, reduced adverse effects, and improved survival. This systematic review
determined if there are socio-economic inequalities in utilization of predictive biomarker tests and/or biological and
precision cancer therapies.
Methods: MEDLINE, Embase, Scopus, CINAHL, Web of Science, PubMed, and PsycINFO were searched for peer-
reviewed studies, published in English between January 1998 and December 2019. Observational studies reporting
utilization data for predictive biomarker tests and/or cancer biological and precision therapies by a measure of
socio-economic status (SES) were eligible. Data was extracted from eligible studies. A modified ISPOR checklist for
retrospective database studies was used to assess study quality. Meta-analyses were undertaken using a random-
effects model, with sub-group analyses by cancer site and drug class. Unadjusted odds ratios (ORs) and 95%
confidence intervals (CIs) were computed for each study. Pooled utilization ORs for low versus high socio-economic
groups were calculated for test and therapy receipt.
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Results: Among 10,722 citations screened, 62 papers (58 studies; 8 test utilization studies, 37 therapy utilization
studies, 3 studies on testing and therapy, 10 studies without denominator populations or which only reported
mean socio-economic status) met the inclusion criteria. Studies reported on 7 cancers, 5 predictive biomarkers tests,
and 11 biological and precision therapies. Thirty-eight studies (including 1,036,125 patients) were eligible for
inclusion in meta-analyses. Low socio-economic status was associated with modestly lower predictive biomarker
test utilization (OR 0.86, 95% CI 0.71–1.05; 10 studies) and significantly lower biological and precision therapy
utilization (OR 0.83, 95% CI 0.75–0.91; 30 studies). Associations with therapy utilization were stronger in lung cancer
(OR 0.71, 95% CI 0.51–1.00; 6 studies), than breast cancer (OR 0.93, 95% CI 0.78–1.10; 8 studies). The mean study
quality score was 6.9/10.
Conclusions: These novel results indicate that there are socio-economic inequalities in predictive biomarker tests
and biological and precision therapy utilization. This requires further investigation to prevent differences in
outcomes due to inequalities in treatment with biological and precision therapies.
Keywords: Precision medicine, Molecular targeted therapy, Immunotherapy, Biological therapy, Pharmacogenomic
testing, Drug utilization, Socio-economic factors, Meta-analysis
Background
Traditional cancer treatments (chemotherapy, surgery,
and radiotherapy) are subject to inequalities in utilization
by socio-economic status [1]. These socio-economic
inequalities have persisted over time and exist across can-
cers, healthcare systems, and treatments [2, 3]. Individuals
with a lower socio-economic status are less likely to
receive conventional treatments, and this may contribute
to poorer cancer outcomes in this group [4].
Increasingly, systemic treatments targeted at cancer
biology (e.g., tyrosine kinase inhibitors and monoclonal
antibodies) are being integrated into cancer clinical care.
These agents are expensive (immunotherapy can cost, in
US dollars, $100,000 per patient annually) and may only
have efficacy in selected sub-populations [5]. Hence,
stratifying patients by molecular pathology to predict the
likelihood of tumor response and adjusting therapy
accordingly is now routinely recommended (see, for ex-
ample, [6]). This move towards biological and precision
therapies is reflected in the cancer drug development
pipeline; for example, in 2019, 450 new cancer drug can-
didates were immunotherapies [7].
Socio-economic inequalities in biological and precision
therapy utilization remain largely unexplored. Some
speculate that using molecular information to target
cancer treatment potentially provides a solution to current
treatment inequalities [8]. Others argue that novel cancer
therapies, because of their cost, disproportionately favor
those with more resources and, therefore, may widen
inequalities further [9–11].
As novel cancer therapies and their associated predict-
ive biomarker tests offer opportunities for increased
tumor response, reduced adverse effects, and improved
survival, it is important to understand whether there are
inequalities in their receipt [12, 13]. This systematic re-
view and meta-analysis integrated the existing research
to investigate the relationship between socio-economic
status and utilization of biological and precision cancer
therapies and their associated predictive biomarker tests.
Methods
The review was registered with the international database
of prospectively registered systematic reviews, PROSPERO
(CRD42019140016), and is reported according to the
Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) [14] (Additional file 1: Supple-
mentary methods 1).
Search strategy and study selection
Searches were performed in seven databases (MEDLINE,
Embase, Scopus, CINAHL, Web of Science, PubMed,
and PsycINFO) for articles published between January
1998 and December 2019. This time period reflects the
licensing and approval of trastuzumab in the USA—con-
sidered a crucial time marker in the precision therapy
field. Therapies of interest included the following: tar-
geted therapy (targeting either oncogene addiction or
synthetic lethality with activity restricted to tumors with
appropriate biomarker status), biologics (where no
predictive biomarker is included in the license), and
immune checkpoint inhibitors. Therapies targeting hor-
mone receptors were excluded as these agents have been
in use since the early 1970s [15]. Search terms covering
socio-economics status, tests, and therapies were devel-
oped; a full search strategy is available in Additional file
1: Supplementary methods 2. Reference lists of eligible
articles were also reviewed.
The inclusion criteria for full-text papers, published
1998 onwards and written in English, were determined
as follows in terms of PICOS (Population, Intervention,
Comparison, Outcome, and Setting). Population: solid
tumor cancer diagnosis (any age or sex). Intervention:
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receipt of either a predictive biomarker test or biological
and precision therapy (or both). Studies reporting
biological and precision therapies administered with an
adjuvant (e.g., chemotherapy) were eligible as long as it
was clear how many patients received the biological or
precision therapy. Only predictive biomarker tests of
pharmacological response to targeted treatment were
included. Comparison: it was not a requirement that a
comparator was reported but where noted, and the
following comparator details were extracted—a clinical
alternative, no biological and precision therapy and/or
predictive biomarker tests, or no treatment. Outcome:
utilization data reported by a socio-economic status
measure (e.g., percent of persons living below the
poverty line, median household income). Setting: retro-
spective or prospective observational design (including
randomized controlled trials analyzed as observational
cohorts). Full inclusion criteria are listed in Additional
file 1: Supplementary methods 3.
Screening of titles and abstracts was conducted by one
author (RN) only. All articles selected for full-text review
were independently checked by a second author (AT).
Disagreements were discussed and, if necessary, resolved
with a third author (LS). Agreement between reviewers
was excellent (κ = 0.93) [16].
Data extraction and quality assessment
Data was extracted by one author (RN) and checked by
another (RD). Disagreements were resolved through
discussion with the review team (AG, AT, LS, and RD).
In instances of missing or inconsistent data, study
authors were contacted. Where there was no response,
data was documented as not reported, or the paper
excluded. In the event of multiple publications reporting
identical or heavily overlapping study populations (e.g.,
same registry, cancer, stage, age group, and time period),
data was extracted from the earliest publication, and
where there was more than one publication from the
same year, extraction first prioritized the publication
reporting an income-based socio-economic measure
and, second, one reporting multiple socio-economic
measures. If more than one multivariable analysis was
conducted, information was extracted from the most
comprehensive adjusted model.
Data was extracted on author(s); publication year;
country; data source; number in study population;
cancer diagnosis time frame, patient age(s), cancer stage,
and registry coverage; socio-economic measure and unit;
numbers receiving predictive biomarker test/biological
and precision therapy, overall and by socio-economic
group (numerator and, where available, denominator);
comparator(s) (where appropriate); and measures of as-
sociation for not receiving testing/treatment by socio-
economic status (e.g., ORs, 95% CIs, and p values). All
eligible studies were quality appraised using a modified
version of the ISPOR checklist for retrospective database
studies. Focus in particular was paid to data sources,
statistical results of interest, and generalizability of
conclusions drawn [17]. The tool had ten features each
scored as 0, 0.5, or 1 (Additional file 1: Supplementary
methods 4). Appraisal was conducted independently by
two authors (RN and RD), with disagreements resolved
through discussion with a third author (AT), and
consensus (AT).
Synthesis of evidence
Data was synthesized using a summary of findings table.
Where not reported, percentages utilizing biological and
precision therapies and/or predictive biomarker test by
socio-economic sub-group were calculated from data
reported in the paper or supplied by authors, and un-
adjusted OR for low compared to high socio-economic
status were computed for test/therapy receipt. Studies
were heterogeneous in terms of outcome analyses (test/
therapy receipt or non-receipt), socio-economic compar-
isons made, whether ORs (crude or adjusted) were re-
ported, and the variables that any adjusted ORs were
controlled for. Unadjusted ORs were therefore computed
to enable inclusion of as many studies as possible in a
consistent way. “Low” socio-economic status was defined
as the lowest socio-economic sub-group in each article
and “high” socio-economic status as the top sub-group.
Meta-analyses were performed using random-effects,
Mantel-Haenszel methods. These assessed the likelihood
of (i) test receipt and (ii) treatment receipt by low socio-
economic status. Eligibility criteria for studies to be in-
cluded in the meta-analysis were as follows: unadjusted
low and high socio-economic utilization data for one
measure of socio-economic status reported and an inde-
pendent sampling frame (no data overlap with another
study/paper). In the primary analyses, results relating to
an income measure (or, failing that, education, or other-
wise, the reported measure) were included. This
reflected the dominance of USA studies within the
evidence base, where there are cost implications for drug
access [18]. Where multiple papers included study
populations from the same or related databases that
overlapped in terms of period of diagnosis/treatment,
the publication reporting the largest total number of
patients was entered into the meta-analysis.
For predictive biomarker tests, results were grouped
by cancer site (breast, colorectal, lung, and melanoma).
Those for biological and precision therapies were
grouped by drug class (targeted therapy, biologic, and
immunotherapy), while separate pre-specified sub-group
analyses were conducted for breast cancer, lung cancer,
and all other cancers (sub-grouped by cancer type: colo-
rectal, head and neck, hepatobiliary, melanoma, mixed,
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renal cell). A final post hoc sub-group analysis was
performed for the Surveillance, Epidemiology, and End
Results program (SEER) versus non-SEER registry stud-
ies. Testing for sub-group differences was computed
where appropriate. Two post hoc sensitivity analyses
(one involving substituting included studies with those
excluded due to overlapping sampling frames and the
other exploring USA versus non-USA healthcare set-
tings) were conducted to determine the robustness of
the results. The I2 statistic was calculated to estimate the
degree of statistical heterogeneity [19], and funnel plots
were produced to assess publication bias in analyses of
ten plus studies [20]. Statistical analyses were conducted
using RevMan 5.3.
Results
Search results
The search identified 17,047 citations. After removal of
duplicates, titles and abstracts of 10,722 records were
screened for eligibility. After title and abstract screening,
551 records progressed to full-text review. Overall, 62
papers (reporting 58 independent studies) met the inclu-
sion criteria (Fig. 1) and were included in the review.
Eight studies reported utilization data for predictive
biomarker tests [21–28], thirty-seven studies (41 papers)
reported utilization data for biological and precision
therapies [29–65], and 3 studies reported both [66–68].
Ten papers (Additional file 1: Table S1) had no denom-
inator populations or only reported an average measure
of socio-economic status (e.g., mean household income),
and were excluded from inclusion in the meta-analysis
and are not discussed further [69–78].
Study characteristics
The 48 included studies covered 7 cancers, 5 predictive
biomarker tests, and 11 biological and precision therapy
classifications, of which bevacizumab (12 studies) [41–
45, 54–56, 58, 59, 64, 65] and trastuzumab (11 studies)
[29–39] were most common. Most studies were in the
USA (n = 42) [21, 22, 25–35, 40–68], and a majority ana-
lyzed SEER registry data (n = 27) [21, 22, 25, 29–33, 41,
42, 45, 47, 49, 50, 54–59, 61–64, 66–68] (Additional file
1: Fig. S1). Of the SEER data studies, 19 [29–32, 41, 42,
47, 49, 54–59, 61–64, 68] were SEER Medicare (i.e., in-
cluded patients ≥ 65). The remaining studies were from
Canada (4 studies) [23, 36–38], China (1 study) [39], and
Ireland (1 study) [24]. Forty-six studies reported one or
more area-based socio-economic status measure, and
only two utilized individual-based measures [34, 68]. Six
SES measures (poverty, income, education, employment,
deprivation, and socio-economic status aggregate score)
were reported. For nine studies, utilization was only
available as percentages [24, 29, 32, 52, 54, 56, 61, 66,
67]. Study characteristics are summarized in Additional
file 1: Table S2.
Seven papers, pertaining to four studies, reported the
same data from the same registry [38, 43, 45, 79–82].
Sixteen papers (covering 8 studies) overlapped in their
study populations (cancer site, stage, years of diagnosis
time frames, patients’ age) [29–32, 36, 37, 41–44, 49, 50,
54, 55, 67, 68]. Two studies did not report unadjusted
drug and/or test utilization data [40, 58]. This left 38
studies (including 1,036,125 patients) which were in-
cluded in the meta-analysis [21–29, 31, 33–35, 37–39,
42, 44–49, 51–54, 56, 57, 59–66, 68].
Quality appraisal
The 48 studies scored in the range 4–10, out of a pos-
sible 10 (mean = 6.9, median = 6.5) (Additional file 1:
Table S3). Papers scored well regarding data source(s),
study populations, and reporting socio-economic defini-
tion(s). Discussion of results with reference to the role
of socio-economic status, statistical analysis with sum-
mary measures like OR, and explanations for confounder
selection were often reported poorly.
Predictive biomarker testing
Eleven studies reported data of interest for five predict-
ive biomarker tests [21–28, 66–68]. Ten studies were in-
cluded in the meta-analysis [21–28, 66, 68]. These
covered the following cancers: breast (4 studies) [21–24],
colorectal (3 studies) [25–27], melanoma (1 study) [66],
and non-small cell lung (2 studies) [28, 68]. The pooled
OR for predictive biomarker test receipt for low socio-
economic status was 0.86 (95% CI 0.71–1.05; I2 = 86%;
10 studies) (Fig. 2). This pattern was consistent across
cancer sub-groups (4 breast cancer studies, 2 lung
cancer studies, and 1 melanoma study) but was only
significant in colorectal cancer (0.76, 95% CI 0.65–0.88;
3 studies).
Biological and precision therapies: primary analysis
Association of socio-economic status with biological and
precision therapy receipt was reported in 40 studies
[29–68]. Thirty of which were included in the meta-
analysis [29, 31, 33–35, 37–39, 42, 44–49, 51–54, 56, 57,
59–66, 68]. The overall pooled OR for receipt of bio-
logical and precision therapy for patients from low
socio-economic status was 0.83 (95% CI 0.75–0.91; I2 =
85%; 30 studies) (Fig. 3). Sub-group analysis suggested
stronger associations with immunotherapy utilization
(0.82, 95% CI 0.78–0.86; 7 studies) than other therapy
classes (14 targeted therapy and 9 biological therapy
studies), but the test for sub-group differences was not
significant (Fig. 3). Sensitivity analyses which substituted
included studies for excluded studies with overlapping
sampling frames confirmed the robustness of results
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(0.80, 95% CI 0.72–0.88; I2 = 86%; 30 studies). Similar re-
sults were also observed in sensitivity analyses when only
USA studies were considered (0.82, 95% CI 0.74–0.91,
I2 = 85%, 27 studies). For full sensitivity analyses results,
see Additional File 1: Fig. S2.
Biological and precision therapies: sub-group analyses
For breast cancer, 11 studies reported the association of
socio-economic status with the human epidermal growth
factor receptor 2 (HER2) targeting monoclonal antibody
trastuzumab [29–39] and one with immunotherapy [40].
Eight studies were eligible for meta-analysis [29, 31, 33–
35, 37–39]. The pooled OR for receipt of trastuzumab in
those with low compared to high socio-economic status
was 0.93 (95% CI 0.78–1.10; I2 = 68%) (Fig. 4).
Nine lung cancer studies evaluated socio-economic
status with biological and precision therapy receipt [41–
47, 67, 68]. Four of these reported bevacizumab [41–44],
2 tyrosine kinase inhibitors [67, 68], 1 both bevacizumab
and tyrosine kinase inhibitors [45], 1 immunotherapy
[46], and 1 biological therapies (mostly bevacizumab)
[47]. Six were eligible for meta-analysis [42, 44–47, 68],
and the pooled OR for receipt of biological and precision
therapies in those of low compared to high socio-
economic status was 0.71 (95% CI 0.51–1.00; I2 = 95%)
(Fig. 5).
Twenty studies reported data of interest for 6 other
cancers: hepatobiliary (4 studies) [48–51], melanoma (3
studies) [52, 53, 66], colorectal (8 studies) [40, 54–60],
renal cell carcinoma (1 study) [61], and head and neck
cancer (2 studies) [62, 63]. A further two studies re-
ported data on more than one cancer [64, 65]. Studies
referenced the following 7 treatments: immunotherapy
[40, 48, 52, 53, 60], bevacizumab [54–56, 58, 59, 64, 65],
Fig. 1 Study selection and exclusion according to the PRISMA statement
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sorafenib [49–51], ipilimumab [66], targeted biologics
[57], IL-2 [61], and cetuximab [62, 63]. Sixteen studies
could be combined into meta-analyses [48, 49, 51–54,
56, 57, 59–66], giving a pooled OR for receipt of bio-
logical and precision therapies for low socio-economic
status of 0.84 (95% CI 0.76–0.94; I2 = 73%) (Additional
file 1: Fig. S3). The test for sub-group differences
between breast, lung, and all other cancers was not
significant (Additional file 1: Fig. S4).
Discussion
This is the first systematic review and meta-analysis to
examine whether there are inequalities in novel cancer
therapeutics and/or associated testing use. Overall, the
findings show that there are statistically significant
socio-economic inequalities in biological and precision
therapy utilization; those with a low socio-economic sta-
tus were 17% less likely to be treated with precision
therapies. An effect of similar magnitude was observed
in test receipt, but did not achieve statistical significance.
The finding that differences are present in novel
cancer treatments is consistent with previous systematic
reviews documenting traditional treatment inequalities
[2, 3]. Similar socio-economic inequalities have also been
observed across the cancer care pathway (from screening
[83], to diagnosis [84], and timeliness of referral and
treatment receipt [85] through to survival [86]).
Combined, this suggests that low socio-economic status
remains a barrier to treatment access and cancer care,
despite advances in treatment.
The strength of socio-economic inequalities varied
with cancer type: the effect estimate for receipt of
biological and precision therapies was stronger for lung
cancer (incidence of which is related to low socio-
economic status) than other cancers. It is not clear why
this is so, although the risk of some cancers (including
lung) is associated with health behaviors (e.g., smoking)
[87]. It is possible that these health behaviors, alongside
other factors (which, themselves may be a consequence
of the health behaviors), such as multi-morbidity, could
influence a healthcare professional’s decision to offer or
Fig. 2 Forest plot showing predictive biomarker test utilization odds (sub-grouped by cancer type) for low compared to high socio-economic
status. ALK, anaplastic lymphoma kinase; BRAF, proto-oncogene B-Raf; HER2, human epidermal growth factor receptor 2; KRAS, oncogene KRAS;
SES, socio-economic status
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initiate, or a patient’s choice to receive, cancer treatment
[88]. While such individual behavioral factors warrant
further investigation, they need contextualizing within
the wider determinants of health (i.e., the social, eco-
nomic, cultural, and clinical level factors) which are also
associated with known treatment barriers [89].
The socio-economic inequalities in testing and therapy
utilization in breast cancer were less pronounced, des-
pite the majority of research focusing on this cancer.
This finding, along with a previous systematic review
concluding equivocal associations between socio-
economic status and trastuzumab uptake [90], suggests
that low socio-economic status may be less of a treat-
ment barrier in breast cancer, at least as far as newer
therapies are concerned. One possible explanation for
this may be that breast cancer sub-type differentiation
and the practice of hormone receptor status testing, and
basing treatment on these results, are well established
and routinely embedded in clinical practice (originating
in the 1970s following the discovery of the estrogen re-
ceptor) [91]. Hence, our findings support the wider con-
cept of the inverse equity hypothesis [92]: that is, that
while new interventions may temporarily widen inequal-
ities by disproportionately favoring those with resources
Fig. 3 Forest plot showing biological and precision therapy utilization odds for all cancers (sub-grouped by drug class) for low compared to high
socio-economic status. CI, confidence interval; SES, socio-economic status
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enabling priority access, over time this narrows as
treatment access “trickles down” and becomes standard
clinical practice [93, 94].
In relation to predictive biomarker testing more
generally, the observation that there is reduced
utilization with respect to socio-economic status builds
on previously documented relationships between factors
associated with socio-economic status and test receipt
(e.g., negative association between smoking and epider-
mal growth factor receptor (EGFR) and anaplastic
lymphoma kinase (ALK) abnormalities) [95]. Previous
work also highlights that test patterns vary temporally
and spatially [96, 97], as well as with respect to patient
demographics (e.g., age) [98]. This suggests that testing
access is complex. Nevertheless, the observation that low
socio-economic status may reduce access to testing has
important implications. First, utilization barriers occur
at points other than just therapy receipt, a finding
echoed by Cancer Research UK who highlighted that
many colorectal and non-small cell lung cancer patients
potentially eligible for targeted treatments did not
receive molecular testing [99]. Second, if multiple bar-
riers to novel therapy utilization exist, then sophisticated
solutions are likely required to prevent cancer
inequalities widening further. In the first instance, fur-
ther monitoring of inequalities is required. However,
given the rapidly evolving nature of the precision oncol-
ogy field, and the fact that routine datasets generally lack
good data on newly licensed therapies and tests, an ap-
preciation of how such information might be captured
in future observational studies is required, especially
those that are large-scale and population-based. Analysis
of new data sources, rich in biological and precision
therapies (e.g., UK’s Systemic Anti-cancer Therapy data-
set) or predictive biomarker test information (e.g., USA’s
Flatiron Health electronic healthcare records database),
may provide the first steps here. Encouragement of data
collection to enable audit of treatment access would
inform development of solutions to respond to any
inequalities noted (e.g., low-income assistance programs,
investigating access barriers in problem areas) [9].
This is the first comprehensive meta-analysis on this
important and growing area of practice, and brings
together data on over 1 million patients. Despite this,
the study does have several limitations. First, there are
challenges comparing studies reporting different mea-
sures of socio-economic status. There was no one con-
sistent measure used, and even when studies appeared
Fig. 5 Forest plot showing biological and precision therapy utilization odds in lung cancer for low compared to high socio-economic status. CI,
confidence interval; SES, socio-economic status
Fig. 4 Forest plot showing biological and precision therapy utilization odds in breast cancer for low compared to high socio-economic status. CI,
confidence interval; SES, socio-economic status
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to use the same measure (e.g., income), how the variable
was categorized (e.g., what was considered “high”; num-
ber of sub-groups considered) differed. For most studies,
there was considerable variation between what was classi-
fied as “high” and “low” socio-economic status, meaning
that true differences were unlikely to be attenuated by a
lack of variability. However, almost all studies used area-
based socio-economic measures, so the ecological fallacy
in inference is a risk. Secondly, determining OR from
raw data disregards adjustments for confounders; this
along with variations in study sampling frames may in
part explain the high heterogeneity observed. It also
means that the possibility cannot be entirely excluded
that any associations seen in the meta-analyses could be
explained by uncontrolled confounding. Third, single re-
viewer title and abstract screening, while considered ac-
ceptable by the Cochrane Collaboration [100], may have
erroneously excluded relevant studies. Finally, any con-
clusions drawn here are time specific and may not fully
reflect all inequalities present within the system.
The review also highlights limitations in the evidence
base. For example, sub-group analyses require care in
interpretation where study numbers are small. The
majority of studies reported data from non-universal
healthcare systems and recorded in SEER Medicare
registries. As the relevance of socio-economic indicators
varies across the life course, measures such as median
household income may be less meaningful in retired
SEER populations [101]. In such circumstances, eligibil-
ity for Medicare may be more important in addressing
one of the most important barriers to care in the USA—
that of having health insurance. Similarly, as employ-
ment is often tied to insurance coverage in non-
universal healthcare systems like the USA, this choice of
socio-economic indicator could be an additional factor
related to utilization outcomes in the under 65 age
group other than income alone. The generalizability of
conclusions drawn to patients outside the USA and age
groups younger than 65 years must be questioned.
Having said this, studies from other countries docu-
mented similar patterns in inequality [24, 37, 39].
Moving forward, consideration of data from other regis-
tries (e.g., Scandinavian datasets known to be rich in
socio-economic detail) would be valuable. The SEER
registry also underrepresents minority populations. This
limitation may be important given the links between eth-
nicity and genetics [102–104]. Despite these limitations,
among all analyses, there was no clear observable
evidence of publication bias (Additional file 1: Fig. S5).
Future research should focus on investigating the rea-
sons for inequalities around these novel therapies. Con-
sideration of testing as a treatment barrier requires
prioritization, and work investigating clinician, patient,
and family roles in decision-making around testing and
treatment receipt is crucial. This is even more pertinent
given the projected increases in panel sequencing testing
costs and the growing number of therapeutic agents en-
tering clinical practice. To aid further work in this area,
it would be helpful if researchers critically evaluated the
relationships between the different measures of socio-
economic status in healthcare utilization research: for
example, individual versus population measures, single
versus aggregate measures, or the various single
measures such as education or income. Doing so ac-
knowledges that there is not one standardized, superior
socio-economic measure to select. Rather, that as all in-
dicators have limitations and the constraints of current
dataset access may restrict the feasibility of further
measurement, the magnitude of inequalities observed as
well as the ability to make cross-study comparisons re-
quires contextualizing in any future findings. From a
practice perspective, policymakers and clinicians need to
be aware of the potential barriers to biological and preci-
sion therapy beyond patients’ tumor molecular profiles.
Revising guidelines to include a focus on reducing in-
equalities would assist with such prioritization.
Conclusions
There are socio-economic inequalities in the utilization
of both predictive biomarker tests as well as biological
and precision cancer therapies. This requires further in-
vestigation to prevent differences in outcomes due to in-
equalities in treatment with biological and precision
therapies.
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